News Releases

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms

News tagged ‘ProstateCancer’ clear

  • Androgen deprivation therapy — one of the most common treatments for prostate cancer — may increase the risk of death from heart disease in patients over age 65, according to a new study by researchers at Dana-Farber Cancer Institute, Brigham and Women's Hospital and other institutions.

Tags: ProstateCancer

  • The FDA's approval of Provenge®, a prostate cancer vaccine, marks a new era of using patients' immune systems to treat cancer.

Tags: ImmuneSystem, ProstateCancer, TranslationalResearch, Immunotherapy

  • Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health in Boston and the Irish Cancer Society have formed the Boston-Ireland Prostate Cancer Collaboration. This new entity will conduct and facilitate exchanges of researchers and knowledge between Boston and Ireland.

Tags: BasicResearch, ProstateCancer

  • Practice-changing clinical research conducted at the Dana-Farber Cancer Institute Department of Biostatistics and Computational Biology was featured at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting Plenary Session.

Tags: BreastCancer, ProstateCancer

  • Prostate tumors that carry a "signature" of four molecular markers have the potential to become dangerously metastatic if not treated aggressively, Dana-Farber Cancer Institute researchers report in an online study published by the journal Nature.

Tags: ProstateCancer, Genetics

  • Dana-Farber's Levi Garraway, MD, PhD, has been selected as one of 26 Howard Hughes Medical Institute investigators.

Tags: Genomics, Honors, ProstateCancer

  • Dana-Farber researchers and colleagues report that men with newly diagnosed metastatic, hormone-sensitive prostate cancer lived more than a year longer when they received a chemotherapy drug as initial treatment instead of waiting for the disease to become resistant to hormone-blockers.

Tags: ProstateCancer

  • Dana-Farber researchers have demonstrated that a hormone-depleting drug can help eliminate or nearly eliminate aggressive prostate cancers that have yet to spread beyond the prostate.

Tags: Hormones, ProstateCancer, TranslationalResearch

  • Immunotherapy, genomic profiling, and investigating game-changing drug therapies topped the list of most important cancer research and clinical developments at Dana-Farber Cancer Institute in 2014.

Tags: EGFR, Genomics, LungCancer, OvarianCancer, ProstateCancer, Lymphoma, Immunotherapy

  • First study of the genomic composition of prostate cancer shows many patients have gene mutations that can be targeted with existing or potential drugs.

Tags: Genomics, ProstateCancer, TargetedTherapy

Showing 1-10 of 26 items